Exploring Barriers and Facilitators to Participation of Male-to-Female Transgender Persons in Preventive HIV Vaccine Clinical Trials

详细信息    查看全文

• 作者：Michele Peake Andrasik (1)
  Ro Yoon (2)
  Jessica Mooney (3)
  Gail Broder (4)
  Marcus Bolton (5)
  Teress Votto (6)
  Annet Davis-Vogel (7)
  
• 关键词：HIV ; Vaccine ; Transgender women
• 刊名：Prevention Science
• 出版年：2014
• 出版时间：June 2014
• 年：2014
• 卷：15
• 期：3
• 页码：268-276
• 全文大小：
• 参考文献：1. Bockting, W. O., Rosser, B. R. S., & Scheltema, K. (1999). Transgender HIV prevention: Implementation and evaluation of a workshop. / Health Education Research, 14, 177-83. CrossRef
  2. Bockting, W. O., Robinson, B. E., & Rosser, B. R. S. (1998). Transgender HIV prevention: A qualitative needs assessment. / AIDS Care, 10, 505-26. CrossRef
  3. Boyce, S., Barrington, C., Bolanos, H., Arandi, C. G., & Paz-Bailey, G. (2012). Facilitating access to sexual health services for men who have sex with men and male-to-female transgender persons in Guatemala City. / Culture, Health and Sexuality, 14, 313-27. CrossRef
  4. Clements-Nolle, K., Marx, R., Guzman, R., & Katz, M. (2001). HIV prevalence, risk behaviors, health care use, and mental health status of transgender persons: Implications for public health intervention. / American Journal of Public Health, 91, 915-21. CrossRef
  5. Edwards, J. W., Fisher, D. G., & Reynolds, G. L. (2007). Male-to-female transgender and transsexual clients of HIV service programs in Los Angeles County, California. / American Journal of Public Health, 97, 1030-033. CrossRef
  6. Elifson, K. W., Boles, J., Posey, E., Sweat, M., Darrow, W., & Elsea, W. (1993). Male transvestite prostitutes and HIV risk. / American Journal of Public Health, 83, 260-62. CrossRef
  7. Grant, J. M., Mottet, L. A., Tanis, J., Harrison, J., Herman, J. L., & Keisling, M. (2011). / Injustice at Every Turn: A Report of the National Transgender Discrimination Survey. Washington, DC: National Center for Transgender Equality and National Gay and Lesbian Task Force.
  8. Institute of Medicine (2011). / The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding. Retrieved from http://www.iom.edu/?media/Files/Report%20Files/2011/The-Health-of-Lesbian-Gay-Bisexual-and-Transgender-People/LGBT%20Health%202011%20Report%20Brief.pdf
  9. Israel, B. A., Eng, E., Schulz, A. J., & Parker, E. A. (Eds.). (2005). / Methods in Community-Based Participatory Research for Health. San Francisco, CA: Jossey-Bass.
  10. Kellogg, T. A., Clements-Nolle, K., Dilley, J., Katz, M. H., & McFarland, W. (2001). Incidence of human immunodeficiency virus among male-to-female transgendered persons in San Francisco. / Journal of Acquired Immune Deficiency Syndromes, 28, 381-84. CrossRef
  11. Kenagy, G. P. (2005). Transgender health: findings from two needs assessment studies in Philadelphia. / Health and Social Work, 30, 19-6. CrossRef
  12. Kenagy, G. P. (2002). HIV among transgendered people. / AIDS Care, 14, 127-34. CrossRef
  13. Minkler, M., & Wallerstein, N. (Eds.). (2003). / Community-Based Participatory Research for Health. San Francisco, CA: Jossey-Bass.
  14. Moustakas, C. (1994). / Phenomenological research methods. Thousand Oaks, CA: Sage.
  15. Mottet, L., & Tanis, J. (2008). / Opening the Door to the Inclusion of Transgender People: The Nine Keys to Making Lesbian, Gay, Bisexual and Transgender Organizations Fully Transgender-Inclusive. New York, NY: National Gay and Lesbian Task Force Policy Institute and the National Center for Transgender Equality.
  16. Moutsiakis, D. L., & Chin, N. P. (2007). Why Blacks do not take part in HIV vaccine trials. / Journal of the National Medical Association, 99, 254-57.
  17. Nemoto, T., Sausa, L. A., Operario, D., & Keatley, J. (2006). Need for HIV/AIDS education and intervention for MFT transgenders: Responding to the challenge. / Journal of Homosexuality, 51, 183-01. CrossRef
  18. Nemoto, T., Operario, D., Keatley, J., Nguyen, H., & Sugano, E. (2005). Promoting health for transgender women: Transgender Resources and Neighborhood Space (TRANS) program in San Francisco. / American Journal of Public Health, 9, 382-84. CrossRef
  19. Nemoto, T., Operario, D., Keatley, J., Han, L., & Soma, T. (2004). HIV risk behaviors among Male-to-Female transgender persons of color in San Francisco. / American Journal of Public Health, 94, 1193-199. CrossRef
  20. Nemoto, T., Luke, D., Mamo, L., Ching, A., & Patria, J. (1999). HIV risk behaviors among male-to-female transgenders in comparison with homosexual or bisexual males and heterosexual females. / AIDS Care, 11, 297-12. CrossRef
  21. Newman, P. A., & Logie, C. (2010). HIV vaccine acceptability: A systemic review and meta-analysis. / AIDS, 24, 1749-756. CrossRef
  22. Newman, P. A., Duan, N., Roberts, K. J., Seiden, D., Rudy, E. T., Swendeman, D., et al. (2006). HIV Vaccine Trial participation among ethnic minority communities: Barriers, motivators, and implications for recruitment. / Journal of Acquired Immune Deficiency Syndromes, 41, 210-17. CrossRef
  23. Sanchez, N. F., Sanchez, J. P., & Danoff, A. (2009). Health care utilization, barriers to care, and hormone usage among male-to-female transgender persons in New York City. / American Journal of Public Health, 99, 713-19. CrossRef
  24. Simon, P. A., Reback, C. J., & Bemis, C. (2000). HIV prevalence and incidence among male-to-female transsexuals receiving HIV prevention services in Los Angeles County. / AIDS, 14, 2953-955. CrossRef
  25. Snelgrove, J. W., Jasudavisius, A. M., Rowe, B. W., Head, E. M., & Bauer, G. R. (2012). “Completely out-at sea-with “two-gender medicine- A qualitative analysis of physician-side barriers to providing healthcare for transgender patients. / BMC Health Services Research, 12, 110. CrossRef
  26. Sobieszczyk, M. E., Xu, G., Goodman, K., Lucy, D., & Koblin, B. A. (2009). Engaging members of the African American and Latino communities in preventive HIV vaccine trials. / Journal of Acquired Immune Deficiency Syndromes, 51, 194-01. CrossRef
  27. Voytek, C. D., Jones, K. T., & Metzger, D. S. (2011). Selectively willing and conditionally able: HIV vaccine trial participation among women at “high risk-of HIV infection. / Vaccine, 29, 6130-135. CrossRef
  28. Young, R. M., & Meyer, I. H. (2005). The trouble with “MSM-and “WSW- Erasure of the sexual-minority person in public health discourse. / American Journal of Public Health, 95, 1144-149. CrossRef
  
• 作者单位：Michele Peake Andrasik (1)
  Ro Yoon (2)
  Jessica Mooney (3)
  Gail Broder (4)
  Marcus Bolton (5)
  Teress Votto (6)
  Annet Davis-Vogel (7)
  
  1. HVTN Social Scientist, HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, E3-300, Seattle, WA, 98109-1024, USA
  2. HIV Vaccine Trials Unit, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  3. The Office of HIV/AIDS Network Coordination (HANC), Seattle, WA, USA
  4. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  5. HIV Vaccine Trials Unit, The Hope Clinic of Emory University, Atlanta, GA, USA
  6. HIV Vaccine Trials Unit, Brigham & Women’s Hospital, Boston, MA, USA
  7. HIV Vaccine Trials Unit, University of Pennsylvania, Philadelphia, PA, USA
  
• ISSN：1573-6695

文摘

Observed seroincidence and prevalence rates in male-to-female (MTF) transgender individuals highlight the need for effective targeted HIV prevention strategies for this community. In order to develop an effective vaccine that can be used by transgender women, researchers must understand and address existing structural issues that present barriers to this group’s participation in HIV vaccine clinical trials. Overcoming barriers to participation is important for ensuring HIV vaccine acceptability and efficacy for the MTF transgender community. To explore barriers and facilitators to MTF transgender participation in preventive HIV vaccine clinical trials, the HIV Vaccine Trials Network conducted focus groups among transgender women in four urban areas (Atlanta, Boston, Philadelphia, and San Francisco). Barriers and facilitators to engagement of transgender women in preventive HIV vaccine clinical trials led to the following recommendations: (a) transgender cultural competency training, (b) creating trans-friendly environments, (c) true partnerships with local trans-friendly organizations and health care providers, (d) protocols that focus on transgender specific issues, and (e) data collection and tracking of transgender individuals. These results have implications for the conduct of HIV vaccine trials, as well as engagement of transgender women in research programs in general.